CRP Point-of-Care Testing (POCT) Significantly Reduces Pediatric Antibiotic Prescriptions by 20-30%

July 5, 2026

Aidian フィンランド

Overview

New findings from two large-scale randomized controlled trials (COORDINATE and ARON) demonstrate that C-reactive protein (CRP) Point-of-Care Testing (POCT) can safely and effectively guide antibiotic use in children with respiratory symptoms or acute illness. The studies, which evaluated thousands of pediatric patients, reported a significant 20-30% reduction in antibiotic prescriptions without compromising patient safety, marking a crucial advancement in global antibiotic stewardship efforts.

In Depth

Background

The global rise of antibiotic resistance stands as one of the most critical public health threats of the 21st century, as designated by the World Health Organization (WHO). A significant accelerator of this crisis is the widespread and often unnecessary prescription of antibiotics. This issue is particularly acute in pediatric care, where antibiotics are frequently prescribed for viral infections, which do not respond to such treatments. To combat this, diagnostic innovators like Finnish company Aidian have been developing high-precision, rapid Point-of-Care Testing (POCT) solutions designed to guide more judicious antibiotic use.

Key Findings

Finnish diagnostics company Aidian has reported robust new evidence from two large-scale randomized controlled trials (RCTs), COORDINATE and ARON (conducted in 2025), validating C-reactive protein (CRP) Point-of-Care Testing (POCT) as an effective tool for guiding antibiotic use in pediatric patients. These trials, involving thousands of children with respiratory symptoms or acute illnesses, were designed to compare antibiotic prescription rates, clinical outcomes, and safety profiles between cohorts managed with CRP POCT guidance versus those relying solely on conventional clinical judgment. The CRP POCT system allows clinicians to rapidly assess a patient’s inflammatory status from a small blood sample within minutes during a consultation. A pivotal finding was an average reduction of 20-30% in antibiotic prescriptions when physicians utilized low CRP values to safely withhold treatment. Crucially, this reduction in antibiotic use did not lead to an increase in clinical deterioration or severe complications; conversely, some patients showed a tendency towards faster recovery, underscoring CRP POCT’s role as a safe and effective complement to clinical decision-making and a vital strategy against global antibiotic overuse. This compelling evidence is poised to significantly shift the paradigm of antibiotic prescribing in pediatric healthcare, with widespread integration of CRP POCT promising to minimize unnecessary antibiotic exposure, safeguard children’s health, and bolster efforts against the escalating antibiotic resistance crisis. Looking ahead, the evolution of POCT devices may involve the integration of additional biomarkers and AI algorithms, paving the way for even more precise identification of infectious agents and the development of personalized treatment strategies, thereby empowering healthcare professionals with faster, more confident diagnostic capabilities and contributing to solving a pressing global health imperative.

Source: https://www.aidian.eu/news/new-evidence-supports-crp-poct-to-guide-antibiotic-use-in-children

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.